Bonomi 1985.

Methods	Randomised Phase II trial
Participants	581 women with squamous cell carcinoma of the cervix considered incurable with surgery or radiation
Interventions	Arm 1: cisplatin 50 mg/m2 iv q21 Arm 2: cisplatin 100 mg/m2 q21 Arm 3: cisplatin 20 mg/m2 iv daily d1‐5 q21 All arms to a maximum dose of 400 mg/m2
Outcomes	Response rates Toxicity OS PFS
Notes	54 excluded (5 no histological confirmation of tumour, 32 wrong cell type, 3 inadequate renal function, 8 second or wrong primary tumour, 2 inadequate performance status, 4 improper pre‐protocol treatment). There were a further 30 women who could not be evaluated (8 inadequate pathological material, 3 improper randomisation, 2 clerical error, 11 never received cisplatin, 1 removed by investigator, 5 inadequate data). ITT analysis not performed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	54 excluded. There were a further 30 women who could not be evaluated. ITT analysis not performed
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	No hint at any other possible biases